Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy

AUTOR(ES)

Yan, Ziying

FONTE

National Academy of Sciences

RESUMO

Adeno-associated viral (AAV) vectors have demonstrated considerable promise for gene therapy of inherited diseases. However, with a packaging size of <5 kb, applications have been limited to relatively small disease genes. Based on the finding that AAV genomes undergo intermolecular circular concatamerization after transduction in muscle, we have developed a paradigm to increase the size of delivered transgenes with this vector through trans-splicing between two independent vectors coadministered to the same tissue. When two vectors encoding either the 5′ or 3′ portions of the erythropoietin genomic locus were used, functional erythropoietin protein was expressed in muscle subsequent to the formation of intermolecular circular concatamers in a head-to-tail orientation through trans-splicing between these two independent vector genomes. These findings will allow for the application of AAV technologies to a wider variety of diseases for which therapeutic transgenes exceed the packaging limitation of present AAV vectors.

Documentos Relacionados

• Gene Therapy Vectors Based on Adeno-Associated Virus Type 1
• Infectious Entry Pathway of Adeno-Associated Virus and Adeno-Associated Virus Vectors
• A role for adeno-associated viral vectors in gene therapy
• A role for adeno-associated viral vectors in gene therapy
• Adeno-associated virus for cystic fibrosis gene therapy